Thursday, 23 Jan 2020

You are here

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

Diabetes is a common comorbid condition in patients with gout and newer approaches to T2DM management include the use of glucagon-like peptide-1 receptor (GLP1) agonists, such as Byetta, Victoza, Trulicity, Ozempic, etc.  SGLT2 inhibitors (e.g., Invokana, Farxiga, Jardiance) inhibit reabsorption of glucose in the kidney and have been shown to lower serum uric acid levels.

This population-based new-user cohort study used claims data from a nationwide commercial insurance database, identifying those with T2DM initiating therapy with an SGLT2 inhibitor or a GLP1 agonist. Patients with a history of gout were excluded. The primary outcome was a new diagnosis of gout.

The study included 295,907 T2DM adults with a newly prescribed an SGLT2 inhibitor or a GLP1 agonist.

The gout incidence rate was lower among patients prescribed an SGLT2 inhibitor (4.9 events per 1000 person-years) than those prescribed a GLP1 agonist (7.8 events per 1000 person-years), with an HR of 0.64 (95% CI, 0.57 to 0.72). 

This analysis did not examine uric acid levels in either cohort. SGLT2 inhibitors have been shown to significantly lower uric acid levels in patients with diabetes, particularly in those with normal renal function (Citation source: http://bit.ly/2QQ6EdH)

 

Add new comment

More Like This

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.

T2T Lowers Mortality in Gout

A Spanish prospective cohort of active, uncontrolled gout patients were followed and showed that failure to reach a target serum uric acid (sUA) level of 6 mg/dl (0.36 mmol/L) or less was associated with a 2-3 fold increase in mortality.